The detrimental roles of these compounds are also sustained by the finding that JAK2 inhibition can reduce the appearance of MPN traits in vivo through the reduction of cytokine delivery in mutant and non-mutant cells [23]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.